Study of QL2107 vs Keytruda for lung cancer after surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial compares a new medicine called QL2107 to the approved drug Keytruda in people with non-small cell lung cancer (NSCLC) that has been removed completely by surgery and treated with chemotherapy. The goal is to see if QL2107 works similarly to Keytruda in preventing the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You had surgery to remove stage II or IIIA non-small cell lung cancer.
- You had chemotherapy after surgery, and it started within 12 weeks of surgery and ended between 3 and 12 weeks before joining the trial.
- A scan (CT or MRI) shows no signs of cancer after surgery and chemotherapy.
- You are able to take care of yourself (ECOG performance status 0 or 1).
- You do not have certain gene changes in your tumor (EGFR mutation or ALK translocation) or an autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a study drug called QL1706 added to standard platinum chemotherapy can lower the chance of lung cancer coming back after surgery. It targets people with stage II to IIIB non-small cell lung cancer who have had their tumor fully removed.
This trial tests a new drug called BAT3306 against the approved drug Keytruda for people with non-small cell lung cancer after surgery. It aims to see if the new drug works as well or better in keeping cancer from coming back.
This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.
This trial tests a new drug, QL2107, combined with chemotherapy, compared to the standard drug Keytruda (pembrolizumab) with chemotherapy. It is for people with stage IV non-squamous non-small cell lung cancer that does not have certain gene mutations (EGFR or ALK).
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a new combination of an immunotherapy drug (QL1706) plus chemotherapy given before and after surgery for people with certain stages of non-small cell lung cancer (NSCLC). The goal is to see if this approach helps shrink the tumor and improves outcomes.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.